<DOC>
	<DOCNO>NCT00424814</DOCNO>
	<brief_summary>In pre-partum phase use antiretroviral therapy mother last trimester pregnancy mandatory . The use HAART pregnancy , usually two nucleoside analogue protease inhibitor expose mother child cumulate toxicity related family . The aim study ass use boost protease inhibitor without nucleoside analogue pre-partum phase woman indication antiretroviral therapy .</brief_summary>
	<brief_title>Prevention HIV1 Mother Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors Pre-partum Phase . ANRS 135 Primeva</brief_title>
	<detailed_description>Recent data French perinatal cohort others indicate HIV-RNA level delivery correlate risk transmission among woman treat antiretroviral agent . Most treatment include zidovudine alone combination . Mitochondrial toxicity relate nucleoside analogues exposure ( zidovudine lamivudine ) report adults infant utero exposure drug . In addition , biological marker genotoxicity nuclear DNA recently show exposed newborn . These issue raise concern risk/benefit multiple therapy context mother child transmission woman meet standard criterion antiretroviral therapy . In woman CD4≥350 VL &lt; 30 000 copies/ml treatment lopinavir/ritonavir achieve rapid control HIV1 viremia 1000 copies/ml without harm term resistance . In study would like assess strict control , safety efficacy regimen compare boost PI + zidovudine lamivudine standard regimen . The treatment start 26 week gestation , follow include safety efficacy parameter well pharmacokinetics plasma genital tract woman , blood/cord ratio , test ARV resistance . Women stop treatment delivery . Infants closely monitor 24 month HIV DNA HIV.RNA-PCR HIV test biochemical haematology usual safety evaluation . In addition frozen sample collect specific evaluation nucleoside analogue foetal mitochondrial nuclear DNA interaction . In term transmission safety , end point would reach viral load 200 copy 8 week treatment . In case failure , would allow sufficient delay treatment modification : i.e . addition NRTI elective caesarian could program .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Assessed 20 24 month pregnancy Pregnancy known 24 week gestation Documented HIV1 infection without indication ARV therapy CD4 count equal 350 per mm3 VL 30 000 copy per ml Naïve PI ( except treatment previous pregnancy ) Informed consent sign HIV2 infection HIV1 group O infection Any pathology related pregnancy Contraindication study drug Unstable hypertension diabetes Known risk premature delivery In case previous treatment protease inhibitor : presence resistance mutation HIV1 protease gene genotyping analysis ( 1 mutation among V32I et I47A , I50V V82A/F/S/T , I84V , L90 M 3 mutation among L10 F/I/R/V , K20/M/R , L24I , L33F , M46I/L , F53L , I54M/L/T/V , L63P , A71L/V/T , )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>HIV mother child prevention</keyword>
	<keyword>HIV Infections</keyword>
	<keyword>Kaletra</keyword>
	<keyword>Combivir</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>